Smith & Nephew

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in Watford, the United Kingdom.

Earnings data Q4 2019

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

LONDON, Aug. 31, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces it will feature its recently expanded Extremities portfolio at the American Academy of Orthopaedic Surgeons 2021 Annual Meeting being held in San Diego, CA. The exciting new portfolio is the result of acquiring the Extremity Orthopaedics business of Integra LifeSciences earlier in 2021, and includes solutions for upper and lower extremity arthritis, and fracture management of the shoulder, elbow, wrist, hand, foot and ankle.

Smith+Nephew launches new total ankle and total shoulder replacement technologies; showcases recently acquired Extremity Orthopaedics portfolio at AAOS

LONDON, Aug. 31, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces it will showcase meaningful new material evidence for its OR3O Dual Mobility Hip System and OXINIUM DH Technology at the American Academy of Orthopedic Surgeons (AAOS) 2021 Annual Meeting in San Diego, CA. New data confirms a reduction in material loss and corrosion for OXINIUM DH (Diffusion Hardened) liners used with the OR3O System – an improvement on equivalent CoCr dual mobility liners within the test.1 In-vitro testing showed a substantial (p

New data underscores material benefits of Smith+Nephew's OXINIUM™ DH Technology and OR3O™ Dual Mobility System for total hip arthroplasty versus Cobalt Chrome liners

LONDON, Aug. 30, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces it will showcase its latest Sports Medicine innovations for joint repair and arthroscopic enabling technologies during the American Academy of Orthopaedic Surgeons 2021 Annual Meeting being held in San Diego, CA. The latest technologies include: FAST-FIX™ FLEX Meniscal Repair System: The only device to offer a surgeon-guided, bendable needle and shaft providing access to all zones of the meniscus.

Smith+Nephew to feature new Sports Medicine technology for joint repair and connected arthroscopic tower during AAOS 2021 Annual Meeting

LONDON, Aug. 30, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces its proprietary OXINIUM (Oxidized Zirconium) Technology has established itself as the best performing bearing with the lowest risk of revision in total hip arthroplasty (THA)1-4, alongside similarly strong clinical performance in knees.5 These results are substantiated by four national and regional joint registries1-4 over the last 20 years with more than 2 million procedures4 to draw from. Through a unique manufacturing process, the zirconium alloy material transforms and hardens through oxidation.

Smith+Nephew's OXINIUM™ Technology recognized as the best performing bearing with lowest risk of revision in total hip arthroplasty

LONDON, Aug. 17, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the launch of WEREWOLF FASTSEAL 6.0 Hemostasis Wand, bringing its leading radio-frequency technology to orthopaedic reconstruction surgeons. Using low temperature thermal energy, the FASTSEAL 6.0 Hemostasis Wand delivers hemostatic sealing during open orthopaedic procedures such as total joint arthroplasty (TJA) – this technology has shown to significantly reduce total blood loss*1 as well as significantly shortening procedure time.

Smith+Nephew expands its leading WEREWOLF™ Technology into total joint arthroplasty with launch of WEREWOLF FASTSEAL 6.0 Hemostasis Wand

Smith & Nephew plc (SNN) CEO Roland Diggelmann on Q2 2021 Results - Earnings Call Transcript

Smith & Nephew Plc (NYSE: SNN) revenues soared in Q2 as COVID-19 restrictions eased and levels of elective surgery returned towards normal in many markets. The Company reported revenues of $1.3 billion, up 48.2%, with underlying growth of 40.3%.

Smith & Nephew Stock Is Trading Lower Despite Posting Surge In Q2 Revenues, Profit

LONDON, July 21, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces study results showing patients treated with just its REGENETEN Bioinductive Implant for partial-thickness rotator cuff tears (>3mm) experienced significantly improved shoulder function during early recovery compared to patients receiving a REGENETEN Implant plus traditional surgical repair, with equivalent efficacy at one year.1   Presented at the AOSSM-AANA Combined 2021 Annual Meeting, study investigators compared the use of a REGENETEN Implant alone (without surgical repair) to a REGENETEN Implant plus traditional surgical repair for the treatment of partial-thickness rotator cuff tears in 227 patients across 19 US surgical centers. Key findings of the study included: Compared with traditional surgical repair, patients reported a significant improvement in shoulder function in the early post-operative period (weeks 2 and 6) with the REGENETEN Implant alone Treatment with the REGENETEN Implant alone demonstrated equivalent efficacy to REGENETEN plus traditional surgical repair with minimal revisions across both treatment groups at 1 year Among all patients receiving a REGENETEN Implant, patients reported significant improvements in pain, function and quality of life from at 1 year compared with pre-surgery values "The results of this pioneering study show that using REGENETEN alone simplifies the surgical procedure.

Study shows Smith+Nephew's REGENETEN™ Bioinductive Implant sets new standard of recovery for partial-thickness rotator cuff tears

Smith+Nephew's (SNN) FAST-FLIX FLEX Meniscal Repair System to provide long-term benefits to patients.

Smith+Nephew's (SNN) New Device to Boost Patient Outcomes

LONDON, July 7, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the launch of its FAST-FIX FLEX Meniscal Repair System, the only device to offer a surgeon-guided, bendable needle and shaft providing access to all zones of the meniscus. Improving access leads to a greater opportunity to repair the meniscus rather than remove it, resulting in long-term benefits to the patient.1-3, 13-15   Building on the 15-year clinical legacy of its FAST-FIX platform, Smith+Nephew's new FAST-FIX FLEX system uses an all-inside approach which may eliminate the need for further incisions, reduce the risk of neurovascular injury, and provide procedural efficiency to support faster operating times.4 The added ability to bend both the needle and shaft enables surgeons access to the mid-body and anterior zones, inaccessible by previous FAST-FIX devices.

Smith+Nephew launches the FAST-FIX™ FLEX Meniscal Repair System; extends all-inside repair possibilities with greater access across all zones of the meniscus*

Smith & Nephew PLC's (LON:SN) growth drivers are “underappreciated” according to analysts at Credit Suisse, who have upgraded the stock to ‘outperform' from ‘neutral' and upped their target price to 1,805p from 1,560p. In a note on Wednesday, the bank said investors “underestimate the combined power of recently-acquired growth drivers with corresponding return leverage mid term” and that they expected the medical equipment group's stock to “reverse its material underperformance over the past 12 months”.

Smith & Nephew growth drivers underappreciated, says Credit Suisse

LONDON, May 5, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the launch of ARIA Home PT, a remote physical therapy product as part of the ARIA suite of solutions. ARIA Home PT offers a customized experience for patients on their time and in their home, while still providing relevant actionable data for clinicians, by leveraging advanced technology, telehealth solutions from licensed physical therapists (PTs) and digital avatar-based guidance.

Smith+Nephew launches ARIA Home PT - a remote physical therapy solution

LONDON, April 30, 2021 /PRNewswire/ -- Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology business, announces the publication of new research showing that clinicians estimated that 45% of their patients with chronic wounds would benefit from greater involvement in their care, and half of these clinicians believed this would enable them to spend more time with other patients.1 The results of the research, published in Wounds International, concluded that the COVID-19 pandemic had been instrumental in providing a real-world opportunity for clinicians to better understand the benefits of greater patient shared care. Clinicians reported a decline in home visits and an increase in remote care via digital communication tools such as video calls, text and email.1 They also claimed to have used alternative dressings or therapies that reduced the frequency of dressing changes.1 Some expressed a concern that when patients are involved in their care they don't change the wound dressing at the right frequency.2 Advanced features such as absorbency and exudate management, present in Smith+Nephew's ALLEVYN LIFE Dressings, were rated as most important when choosing a foam.2 Practitioner attitudes towards encouraging shared care varied globally; in China, the UK and the USA, shared care is a more established approach than in France and Germany, where care is predominately nurse-led.

Smith+Nephew sponsored research shows COVID-19 has accelerated patient involvement in chronic wound care which can be supported by advanced foams such as ALLEVYN™ LIFE Dressing

Smith & Nephew PLC (LON:SN.) reinstated full-year guidance as visibility is improving thanks to the COVID-19 vaccine rollout programmes and healthcare systems reopening to non-urgent surgery.

Smith & Nephew sees the light at the end of the tunnel

LONDON, April 28, 2021 /PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces a new study showing that computer-guided technology for total hip arthroplasty (THA) – such as Smith+Nephew's RI.HIP NAVIGATION – significantly reduces the risk of revision and increases patient satisfaction when using Smith+Nephew implants. The study is the first of its kind using the dataset from the world's largest arthroplasty register (National Joint Registry of England, Wales and Northern Ireland) to investigate the effect of computer-guided THA surgery on implant survivorship.1 The data reported on THA surgery performed using Smith+Nephew hip replacement components implanted for osteoarthritis since 2003.

Computer-guided surgery with Smith+Nephew's hip replacement implants shown to significantly improve survivorship and increase patient satisfaction compared to conventional surgery

LONDON, April 20, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces new enabling technologies for its INTELLIO™ Connected Tower Solution with the introduction of the DOUBLEFLO™ Inflow/Outflow Pump* and 4KO™ (Optimized) Arthroscopes and Laparoscopes. Designed to be simple, effective and connected, the DOUBLEFLO Pump** is able to respond to a surgeon's needs in diverse clinical situations1,2.

Smith+Nephew expands sports medicine wireless arthroscopic tower with new fluid management and 4K surgical imaging technology

LONDON, April 13, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is pleased to announce that its wireless, wearable LEAF Patient Monitoring System has  monitored more than 60,000 patients with over 7 million hours of use, helping to reduce the economic and human costs of pressure injuries. While rates of other hospital-acquired conditions have declined in the US in recent years, hospital acquired pressure injury (HAPI) rates have continued to increase1, leading to an average incremental cost of $21,767 per patient impacted.2 In a randomized clinical trial conducted using the LEAF System, results showed that HAPI odds were reduced by 73%3*, an impact which could help eliminate up to $39 billion in avoidable HAPI costs if expanded nationally.1,2 "We're proud that the LEAF System has reached this major milestone while driving improved patient outcomes and economic savings to healthcare systems.

Seven million hours of patient data shows that Smith+Nephew's wireless, wearable LEAF™ Patient Monitoring System helps prevent hospital-acquired pressure injuries

LONDON, March 25, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces a marketing collaboration with Movendo Technology (Genoa, Italy) that will add personalised robotic patient rehabilitation capability to Smith+Nephew's Real Intelligence enabling technology solutions, creating a fully digitised patient pathway from the pre-op stage to post-rehab phase. The collaboration has launched in Europe and will expand to other regions in the near future.

Smith+Nephew adds Movendo Technology's patient rehabilitation solution to Real Intelligence digital ecosystem

LONDON, March 18, 2021 /PRNewswire/ -- Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology business, is pleased to announce the results of a real-world study from Spain that showed how a switch to ALLEVYN LIFE Foam Dressings helped to significantly reduce dressing change frequency and weekly dressing costs, while improving treatment satisfaction for clinicians and patients in a community setting.*1 At week 4, compared with previous dressings, ALLEVYN LIFE Dressings significantly reduced mean weekly dressing change frequency by 47.1%* 1 and mean weekly dressing costs by 58.7%.

Smith+Nephew's ALLEVYN™ LIFE Foam Dressings halved change frequency, significantly reduced cost and improved treatment satisfaction in real-world study

Smith & Nephew plc (SNN) CEO Roland Diggelmann on Q4 2020 Results - Earnings Call Transcript

Medical device maker Smith & Nephew plc (NYSE: SNN) slips in the premarket after reporting a slump in revenues and profits. Full-year 2020 revenue fell 11.2% Y/Y to $4.6 billion, and operating profit dropped over 60% to $295 million.

Smith & Nephew Maintains Dividend For 2021 Despite Q4 Earnings Hit By COVID-19; Shares Drop

Smith & Nephew PLC (LON:SN) saw its shares slide in early deals as it caught the market on the hop with a disappointing set of results. Shares in the wound care and knee & hip implants specialist were down 7.3% at 1,453p, making them the worst performers in the FTSE 100 after it reported a 7.1% underlying fall in revenue for the final quarter of 2020 to US$1,326mln from US$1,407mln the year before.

Smith & Nephew suffers nasty fall

Smith+Nephew's (SNN) PICO Single Use Negative Pressure Wound Therapy System (sNPWT) considerably reduces surgical site infections complications and provides better patient outcome.

Smith+Nephew's (SNN) PICO sNPWT Study Outcome Encouraging

LONDON, Jan. 27, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is pleased to announce a new publication showing that its PICO Single Use Negative Pressure Wound Therapy System (sNPWT) significantly reduced the odds of surgical site...

Smith+Nephew's PICO™ Single Use Negative Pressure Wound Therapy System again shown to significantly reduce surgical site complications

Activision Blizzard

ALPS Barron's 400 ETF

Siren Nasdaq NexGen Economy ETF

Roku

Twitter

UnitedHealth Group

The rally in 2020 may mean many stocks are not cheap any more, but long-term investors can still find robust stocks to buy in a bull market The post 7 Stocks to Buy for a Continued Run with the Market Bulls appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets

News for Smith & Nephew Stock (SNN)